GFP
BMRN icon

Gryphon Financial Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gryphon Financial Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-28
Closed -$3K – 241
2018
Q2 		$3K Buy
+28
New +$2.45K ﹤0.01% 742

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gryphon Financial Partners's BMRN Position: Q3 2018 in Review

Gryphon Financial Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 28 shares — an estimated $3K sold.

Gryphon Financial Partners first reported a position in BMRN in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 460 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

  • Gryphon Financial Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 28 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Gryphon Financial Partners first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Gryphon Financial Partners's BioMarin Pharmaceuticals position peaked at $3K in Q2 2018.
  • 460 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.